Following on from advice received from the company, NICE has decided to suspend this appraisal from its work programme whilst the company confirm their regulatory filing plans.
As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes.
| Status | Suspended |
| Technology type | Medicine |
| Decision | Selected |
| Process | STA Standard |
| ID number | 4040 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 08 March 2024 | Suspended. Following on from advice received from the company, NICE has decided to suspend this appraisal from its work programme whilst the company confirm their regulatory filing plans. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes. |
| 11 July 2023 | Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin during early July 2024 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately early September 2024. |
| 10 February 2023 | The National Institute for Health and Care Excellence (NICE) has been asked to conduct an appraisal of venetoclax with dexamethasone for treating relapsed or refractory t(11;14)-positive multiple myeloma after lenalidomide and a proteasome inhibitor. We have recently invited stakeholders to respond to a written consultation on the draft scope for this appraisal. Following an update from the company that market venetoclax, NICE will not be progressing with the scoping exercise at this stage. The consultation on the draft scope will now close. Please accept our apologies for any inconvenience. If you have any comments or concerns, please contact the project manager for this proposed appraisal Emily Richards on (44 (0)161 413 4070 or via email on emily.richards@nice.org.uk) |
| 18 January 2023 | In progress. Scoping commenced |
| 28 November 2022 | As you will be aware, the Department for Health & Social Care has asked NICE to conduct an appraisal of Venetoclax with dexamethasone within its marketing authorisation for treating relapsed or refractory t(11;14)-positive multiple myeloma after lenalidomide and a proteasome inhibitor. Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin in mid-July 2023 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately mid-September 2023. |
For further information on our processes and methods, please see our CHTE processes and methods manual